Get the Stockscreener App
6.86
1.93%
0.13
After Hours:
6.80
-0.06
-0.87%
Galecto Inc stock is traded at $6.86, with a volume of 13,795.
It is up +1.93% in the last 24 hours and down -41.27% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$6.73
Open:
$6.78
24h Volume:
13,795
Relative Volume:
0.38
Market Cap:
$8.99M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-3.4129
EPS:
-2.01
Net Cash Flow:
$-36.91M
1W Performance:
-3.11%
1M Performance:
-41.27%
6M Performance:
-60.81%
1Y Performance:
-52.94%
1-Day Range:
$6.78
$7.14
1-Week Range:
$6.55
$7.59
52-Week Range:
$6.50
$23.50
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN
Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN
Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN
Galecto Reports Third Quarter 2024 Financial Results - The Manila Times
(GLTO) On The My Stocks Page - Stock Traders Daily
Galecto price target raised to $10 from $9 at Oppenheimer - Yahoo Finance
How to Take Advantage of moves in (GLTO) - Stock Traders Daily
Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer - MarketBeat
Galecto (NASDAQ:GLTO) Given New $10.00 Price Target at Oppenheimer - MarketBeat
Galecto adds Dr. Amy Wechsler to Board of Directors By Investing.com - Investing.com Canada
Galecto stock hits 52-week low at $6.61 amid market challenges - Investing.com Canada
Galecto adds Dr. Amy Wechsler to Board of Directors - Investing.com
Galecto Appoints Dr. Amy Wechsler to Board - TipRanks
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - The Manila Times
Galecto refocuses on cancer, acquires novel AML drug rights By Investing.com - Investing.com South Africa
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
Galecto stock hits 52-week low at $9.3 amid market challenges - Investing.com
Galecto stock hits 52-week low at $9.3 amid market challenges By Investing.com - Investing.com South Africa
Galecto Expands Oncology Portfolio with Strategic Acquisition - TipRanks
Galecto refocuses on cancer, acquires novel AML drug rights - Investing.com
Galecto Shares Slide on Leukemia Treatment Rights Acquisition - MarketWatch
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - The Manila Times
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
KBW Bank Index (BKX) QuotePress Release - The Globe and Mail
Charter Communications Inc (CHTR-Q) QuotePress Release - The Globe and Mail
Robusta Coffee 10-T (RMK26) Quote - The Globe and Mail
S&P GSCI Index (GNX) QuotePress Release - The Globe and Mail
TSX North American Pref Stock Index (STNU) QuotePress Release - The Globe and Mail
Nuscale Power Corp (SMR-N) QuotePress Release - The Globe and Mail
King Corn's Royal(s) Connection - The Globe and Mail
Trading (GLTO) With Integrated Risk Controls - Stock Traders Daily
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
Boehringer Gets The First Phase III Hit In IPF For A Decade - Scrip
Short Interest in Galecto, Inc. (NASDAQ:GLTO) Drops By 62.1% - Defense World
Skandinaviska Enskilda Banken AB publ Buys New Stake in GitLab Inc. (NASDAQ:GTLB) - MarketBeat
The Gabelli Convertible and Income Securities Fund (NYSE:GCV) Stock Price Passes Above 50 Day Moving Average of $3.83 - MarketBeat
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Stock Price Up 5.4% - MarketBeat
We Think Gamma Communications' (LON:GAMA) Healthy Earnings Might Be Conservative - Yahoo Finance
ABC Glofox records €34m loss due to start-up costs - MSN
Carlson Capital, L.P. Sells 50,000 Shares of Glatfelter Co. (NYSE:GLT) Stock - Defense World
Keeping an Eye on Gray Television, Inc. (GTN) After Insider Trading Activity - Knox Daily
GAMCO Investors (NYSE:GAMI) Sees Unusually-High Trading Volume - Defense World
Carlson entities sell Glatfelter Corp shares worth $91,000 - Investing.com
Ratio Review: Analyzing Gaotu Techedu Inc ADR (GOTU)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GTBP stock touches 52-week low at $1.92 amid market challenges - Investing.com
GitLab Inc. (NASDAQ:GTLB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Understanding GLMD stock ratios for better investment decisions - US Post News
Grupo Financiero Galicia (GGAL) Is Up 3.48% in One Week: What You Should Know - Yahoo Finance
Altshuler Shaham Ltd Buys 1,450 Shares of GitLab Inc. (NASDAQ:GTLB) - Defense World
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):